Answers are grounded in this paper and cite their sources.
Case report shows methyldopa alleviates symptoms of paroxysmal sympathetic hyperactivity in children, suggesting it as a viable treatment option.
Paroxysmal sympathetic hyperactivity (PSH) is a clinical syndrome characterized by intermittent episodes of excessive sympathetic and motor activity, including tachycardia, hypertension, hyperthermia, tachypnea, excessive diaphoresis, and abnormal posturing. Clonidine, an α2-adrenergic agonist, is used as a treatment for PSH, demonstrating efficacy across multiple studies. However, market withdrawal and the lack of a generic alternative in Japan have prompted the need for other therapeutic options. Case 1 was 2-year-old boy with trisomy 13 complicated by holoprosencephaly, severe intellectual disability, and mixed quadriplegia. His PSH had been well-controlled with clonidine, which was successfully replaced with methyldopa after discontinuation of the former. Case 2 was a 1-year-old boy diagnosed with early infantile epileptic encephalopathy caused by a KCNQ2 mutation. PSH symptoms and elevated creatine kinase levels were alleviated with gabapentin and methyldopa. We present the first two pediatric cases of PSH successfully managed with methyldopa, another α2-adrenergic agonist, as an alternative to clonidine. Methyldopa may serve as a promising alternative treatment for pediatric patients with PSH, particularly in settings where clonidine is unavailable. Further studies are required to evaluate the efficacy, safety, and long-term outcomes of methyldopa in this population.
No takes yet. Share an insight, caveat, or question.
Ukai et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: